Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
03/23/2017 03/24/2017 03/27/2017 03/28/2017 03/29/2017 Date
24.875(c) 25(c) 25(c) 25.125(c) 25.45 Last
67 336 93 904 140 734 221 635 161 578 Volume
+0.51% +0.50% 0.00% +0.50% +1.29% Change
More quotes
Financials ( GBP)
Sales 2017 15,0 M
EBIT 2017 -33,6 M
Net income 2017 -33,4 M
Finance 2017 34,2 M
Yield 2017 -
Sales 2018 29,9 M
EBIT 2018 -28,8 M
Net income 2018 -16,0 M
Finance 2018 13,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 6,55x
EV / Sales2018 3,98x
Capitalization 132 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
10:09a VERNALIS : Block listing Interim Review
03/06 VERNALIS : Partners With Servier On Oncology Drug-Discovery
03/06 VERNALIS : and Servier enter into a new drug discovery collaboration strengtheni..
03/06 VERNALIS : New drug discovery collaboration with Servier
02/22 VERNALIS : Unaudited Interim Results for the six months ended 31 December 2016
02/21 VERNALIS : Interim Loss Widens But Market For Flu Drug "Marginally" Up
02/21 VERNALIS PLC : Unaudited Interim Results for the six months ended 31 December 20..
02/16VERNALIS PLC : half-yearly earnings release
02/15 CORVUS PHARMACEUTICALS,INC. (NASDAQ : CRVS) Files An 8-K Other Events
02/14 VERNALIS : Gets USD3 Million Milestone Payment Under Corvus Deal
More news
Sector news : Biotechnology & Medical Research - NEC
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/23PE-backed Orion buys Vernalis  
03/20Vernalis plc's PT cut by N+1 Singer to GBX 28. hold rating.  
03/14A look at a swollen San Joaquin River at Vernalis #caflood #cawx
14
03/06BRIEF-Vernalis Plc enters drug discovery collaboration with Servier  
02/22Vernalis plc downgraded by Zacks Investment Research to hold.  
More tweets
Qtime:6
News from SeekingAlpha
02/21 Vernalis reports 1H results
2016 Vernalis reports FY16 results
2016 Vernalis ADR reports 6M'15 results
2015 Vernalis acquires U.S. rights to extended-release antibiotic
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,65  GBP
Spread / Average Target 157%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-26.10%164
INCYTE CORPORATION39.10%28 429
QUINTILES IMS HOLDINGS..3.48%18 567
LONZA GROUP AG3.12%10 618
CELLTRION, INC.--.--%9 982
SEATTLE GENETICS, INC.22.17%9 187
More Results